Search Bar & Filters
Found 18 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the combination of CGT9486 and sunitinib compared to sunitinib alone in patients with locally advanced, unresectable, or metastatic Gastrointestinal Stromal Tumors GIST. This Phase 3, open-label international trial involves multiple parts, including dose confirmation, drug interaction assessments, and efficacy comparisons. The study also includes substudies focusing on drug-drug interaction potential and first-line treatment in patients with specific genetic mutations KIT exon 9. Approximately 482 patients will participate across these parts.
Actively Recruiting
Researchers are studying the use of subcutaneous under the skin durvalumab combined with recombinant human hyaluronidase rHu in adults with various solid tumors, including non-small cell lung cancer, hepatocellular carcinoma, and limited-stage small cell lung cancer. This Phase I, multicenter trial aims to find a subcutaneous dose that provides similar drug levels in the body as the intravenous form and to evaluate its pharmacokinetics and safety. The trial has two parts Part 1 involves dose escalation with two planned subcutaneous durvalumab dose levels DL1 and DL2 combined with rHu, followed by intravenous durvalumab at set intervals. Part 1 includes participants with different solid tumors. Part 2 begins after identifying the best dose from Part 1 and focuses on participants with unresectable hepatocellular carcinoma receiving the selected subcutaneous dose plus intravenous durvalumab. Some participants with hepatocellular carcinoma may also receive tremelimumab intravenously. Participants will undergo treatment and monitoring for about 17 months, during which researchers will assess drug levels over time and safety outcomes. Regular evaluations include measuring drug concentrations in blood, monitoring for adverse events and dose-limiting toxicities, and assessing disease status. This extensive follow-up helps understand how the drug behaves in the body and its safety profile over time.
Actively Recruiting
Researchers are evaluating HLX22 combined with trastuzumab and chemotherapy as a first-line treatment for patients with HER2-positive locally advanced or metastatic adenocarcinoma of the gastric or gastroesophageal junction. This phase 3, randomized, double-blind study compares this combination against trastuzumab plus chemotherapy with or without pembrolizumab. The trial aims to assess the efficacy and safety of adding HLX22 in this patient population. Participants will be randomly assigned in a 11 ratio to either the experimental group receiving HLX22 15 mgkg plus trastuzumab and chemotherapy XELOX with or without a placebo for pembrolizumab every three weeks, or the control group receiving placebo for HLX22 plus trastuzumab and chemotherapy XELOX with or without pembrolizumab also every three weeks. Treatment continues until clinical benefit is lost, intolerable side effects occur, death, withdrawal, or other protocol-specified reasons. Throughout the study, participants will have their disease progression monitored by an independent radiology review committee using RECIST v1.1 criteria for up to five years, along with overall survival and response rates. Safety will be regularly assessed by tracking adverse events. The study includes multiple assessments to evaluate treatment effects, and participants will be followed for long-term outcomes during the trial period.
Actively Recruiting
The trial investigates treatments for adults with KRASNRAS and BRAF wild-type recurrent, unresectable, or metastatic colorectal cancer who have previously undergone chemotherapy. It compares how long participants live without disease progression and overall survival when treated with two different combinations of chemotherapy and targeted biological agents. This phase 3 study explores differences in outcomes between the use of amivantamab plus FOLFIRI chemotherapy and cetuximab or bevacizumab plus FOLFIRI chemotherapy. Participants are randomly assigned to one of two groups. One group receives amivantamab together with FOLFIRI, a chemotherapy regimen including 5-fluorouracil, leucovorin calcium or levoleucovorin, and irinotecan. The other group receives either cetuximab or bevacizumab with the same FOLFIRI chemotherapy. Treatments are given in 28-day cycles and continue until disease progression is observed on scans or other stopping criteria are met. During the study, participants undergo regular monitoring including radiographic scans to assess disease status and progression-free survival for up to 2 years and overall survival for over 4 years. Researchers also evaluate tumor response rates, duration and time to response, quality of life through questionnaires, side effects, and laboratory tests. The total study duration may extend up to more than 4 years to thoroughly assess treatment outcomes and safety.
Actively Recruiting
This clinical trial is designed to compare the duration participants remain free of disease progression when treated with two different combinations of therapies for adults with KRASNRAS and BRAF wild-type unresectable or metastatic left-sided colorectal cancer. The study focuses on how amivantamab combined with chemotherapy compares to cetuximab combined with chemotherapy in treating this specific cancer type. Participants will be divided into two groups. One group receives amivantamab combined with chemotherapy, either mFOLFOX6 containing 5-fluorouracil, leucovorin calcium or levoleucovorin, and oxaliplatin or FOLFIRI containing 5-fluorouracil, leucovorin calcium or levoleucovorin, and irinotecan hydrochloride. The other group receives cetuximab combined with the same chemotherapy options. Treatments are given in 28-day cycles and continue until the cancer progresses or other reasons require stopping the treatment. Throughout the study, participants will undergo regular evaluations to monitor how long they remain without disease progression, assessed by independent review and investigators. Other assessments include overall survival, response rates, duration of response, quality of life questionnaires, and safety monitoring up to several years. The study spans several years, with primary outcomes measured up to over four years and additional follow-up extending beyond seven years to gather comprehensive data on treatment effects and patient well-being.
Actively Recruiting
Researchers are evaluating the combination of pazopanib with or without abexinostat in patients who have locally advanced unresectable or metastatic renal cell carcinoma RCC. This Phase 3, randomized, double-blind, placebo-controlled study aims to compare the effects of pazopanib plus abexinostat versus pazopanib plus placebo. The study focuses on progression-free survival and other outcomes to understand the potential benefits and risks of adding abexinostat to pazopanib treatment for this condition. Participants will be randomly assigned in a 21 ratio to receive either pazopanib plus abexinostat or pazopanib plus a placebo. Pazopanib is taken daily by mouth throughout each 28-day treatment cycle, while abexinostat or its matching placebo is taken twice daily on specific days within each cycle. If disease progression occurs, patients initially receiving placebo may switch to the combination of pazopanib plus abexinostat. Treatment continues until disease progression, unacceptable side effects, withdrawal, or study closure. Participants will undergo screening within 28 days before starting treatment to confirm eligibility. They will be monitored regularly during treatment cycles with assessments including imaging scans and evaluations of side effects using standard criteria. Outcome measures include progression-free survival, overall survival, response rates, duration of response, and changes in quality of life scores. Follow-up will continue for up to approximately four years, with ongoing safety and efficacy evaluations throughout the study period.
Actively Recruiting
Researchers are studying the long-term safety of pirtobrutinib in people who have previously been treated for chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL. This study welcomes participants who completed the earlier LOXO-BTK-20020 trial to continue receiving the study drug or attend follow-up visits. The study is a Phase 4 treatment trial sponsored by Eli Lilly and Company. Participants will receive pirtobrutinib orally every 4 weeks. There is also a group receiving idelalisib orally. This study is designed as a parallel, non-randomized trial and is expected to last approximately 5 years, allowing continued access to treatment or follow-up for participants from the previous study. During the study, participants will be monitored for treatment-emergent adverse events of grade 3 or higher from the first dose through 30 days after the last dose or start of new anticancer therapy. Researchers will also track overall survival from enrollment in the original study until death from any cause, up to about 93 months. Participants will have regular visits over the study period for safety and health assessments.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of tacabrutideg compared with investigators choice treatments in people with chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL who have previously been treated with both Bruton Tyrosine Kinase inhibitors BTKi and B-cell LeukemiaLymphoma 2 protein inhibitors BCL2i. This study aims to compare how long participants live without their disease worsening under these treatments. The study is a Phase 3, randomized trial sponsored by BeOne Medicines. Participants will be randomly assigned to receive either tacabrutideg taken orally once daily until treatment discontinuation criteria are met, or investigators choice of treatment. The investigators choice includes combinations such as idelalisib plus rituximab for CLL only, bendamustine plus rituximab, or venetoclax plus rituximab retreatment. Some of these drugs are administered orally while others are given intravenously. During the study, participants will be closely monitored for progression-free survival over approximately 36 months, along with overall survival and response rates. Researchers will assess quality of life using specific questionnaires for up to 24 months, and track treatment-emergent adverse events. The study involves regular assessments and evaluations to understand treatment effects and safety over the course of participation, which may last several years until study completion in 2030.
Actively Recruiting
Researchers are comparing the effectiveness of two combinations of drugs, teclistamab with daratumumab and lenalidomide Tec-DR, and talquetamab with daratumumab and lenalidomide Tal-DR, against the combination of daratumumab, lenalidomide, and dexamethasone DRd in adults with newly diagnosed multiple myeloma who are not candidates for stem cell transplant. This Phase 3 trial focuses on evaluating treatment outcomes and survival rates over an extended period. Participants will be randomly assigned to one of three groups one receiving teclistamab by subcutaneous injection combined with daratumumab and oral lenalidomide another receiving talquetamab by subcutaneous injection combined with daratumumab and lenalidomide and the third receiving daratumumab by subcutaneous injection along with oral lenalidomide and dexamethasone, which may be given orally or intravenously. Treatments will be administered according to protocol, with close monitoring throughout the study. During the study, participants will undergo regular evaluations over up to nine years, including assessments of disease progression, survival, response to treatment, and quality of life using various questionnaires. Safety will be monitored through laboratory tests, physical exams, vital signs, electrocardiograms, and tracking of any adverse events. Researchers will also measure drug concentrations and immune responses to the study drugs. Participation may last until disease progression, death, or the end of the study period.
Actively Recruiting
Researchers are evaluating zolbetuximab combined with pembrolizumab and chemotherapy in adults with stomach cancer or gastroesophageal junction GEJ cancer that is HER2-negative, Claudin 18.2-positive, and PD-L1-positive. The study focuses on people with locally advanced unresectable or metastatic disease who may have had prior standard treatments. This phase 3 randomized, double-blind study aims to understand how well zolbetuximab works with other therapies compared to placebo with pembrolizumab and chemotherapy. Participants receive either zolbetuximab or placebo intravenously every 2 or 3 weeks, along with pembrolizumab infusions every 3 or 6 weeks. Chemotherapy is given as either CAPOX oral capecitabine tablets and oxaliplatin infusions or mFOLFOX6 infusions of oxaliplatin, folinic acid, and 5-fluorouracil over several cycles. Treatment continues until cancer progression, intolerable side effects, or another cancer therapy is needed. Pembrolizumab may be given for up to 2 years. During the study, participants visit clinics for treatment infusions, health checks, and scans to monitor cancer changes. Medical problems and side effects are tracked, and tumor samples may be collected if treatment stops due to progression. Follow-up visits and telephone health checks continue after treatment to monitor participants health and cancer status. The study measures overall survival as the main outcome over up to 72 months.
1-10 of 18
1